Compounds > nifedipine

nifedipine and ritonavir

nifedipine has been researched along with ritonavir in 19 studies

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (42.11)	29.6817
2010's	9 (47.37)	24.3611
2020's	2 (10.53)	2.80

Authors

Authors	Studies
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA	1
Bruno-Blanch, L; Gálvez, J; García-Domenech, R	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Rathbun, RC; Rossi, DR; Slater, LN	1
Grant, DJ; Law, D; Schmitt, EA; Zhang, GG; Zhou, D	1
Baeza, MT; Boix, V; Climent, E; Merino, E	1
Back, DJ; Gibbons, SE	1
Cai, W; Jiao, Z; Jin, S; Li, S; Lin, X; Niu, W; Xiang, X; Zhang, M	1
McGrane, IR; Rauser, MS	1

Reviews

1 review(s) available for nifedipine and ritonavir

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

18 other study(ies) available for nifedipine and ritonavir

Article	Year
Rational use of in vitro P-glycoprotein assays in drug discovery. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera	2001
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship	2003
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
First-principle, structure-based prediction of hepatic metabolic clearance values in human. European journal of medicinal chemistry, 2009, Volume: 44, Issue:4 Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index	2014
Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy, 2002, Volume: 22, Issue:10 Topics: Alkynes; Anti-HIV Agents; Antihypertensive Agents; Benzoxazines; Cyclopropanes; Delayed-Action Preparations; Drug Interactions; HIV Protease Inhibitors; Humans; Hypotension, Orthostatic; Male; Middle Aged; Nelfinavir; Nifedipine; Oxazines; Ritonavir	2002
A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses. Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:1 Topics: Calorimetry, Differential Scanning; Crystallization; Drug Stability; Entropy; Models, Chemical; Molecular Structure; Motion; Nifedipine; Phase Transition; Ritonavir; Thermodynamics; Time Factors; Transition Temperature	2007
Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS (London, England), 2007, Jan-02, Volume: 21, Issue:1 Topics: Acute Kidney Injury; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Hypertension; Lopinavir; Male; Middle Aged; Nifedipine; Pyrimidinones; Ritonavir	2007
Response to "Nifedipine-lopinavir/ritonavir severe interaction: a case report". AIDS (London, England), 2007, May-31, Volume: 21, Issue:9 Topics: Anti-HIV Agents; Antihypertensive Agents; Drug Interactions; HIV Infections; Humans; Lopinavir; Nifedipine; Pyrimidinones; Ritonavir	2007
Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. British journal of clinical pharmacology, 2021, Volume: 87, Issue:7 Topics: Antiviral Agents; Area Under Curve; COVID-19 Drug Treatment; Drug Interactions; HIV Infections; Humans; Models, Biological; Nifedipine; Ritonavir; SARS-CoV-2	2021
A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. The Annals of pharmacotherapy, 2023, Volume: 57, Issue:8 Topics: Acute Kidney Injury; Antiviral Agents; Cytochrome P-450 CYP3A; Edema; Humans; Nifedipine; Oliguria; Ritonavir	2023